Global Bleeding Disorders Treatment Market

Bleeding Disorders Treatment Market Size, Share, Growth Analysis, By Disorder Type(Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type(Recombinant Clotting Factors, Plasma-derived Clotting Factors, Desmopressin, Antifibrinolytics), By Drug Class(Plasma Derived Coagulation Factor (Factor VIII, Factor IX, Factor for Von Willebrand Disease, Activated Prothrombin Complex Concentrate)), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35J2106 | Region: Global | Published Date: June, 2024
Pages: 219 | Tables: 101 | Figures: 66

Bleeding Disorders Treatment Market News

  • September 2023: ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, has received approval from the U.S. Food and Drug Administration (FDA). This marks a huge milestone for the primary-of-its-type excessive-sustained thing VIII replacement remedy. 

  • October 2023: Sanofi SA (SASY.PA) has received approval from the U.S. Food and Drug Administration for its remedy designed to deal with hemophilia A, a hereditary bleeding disease. The French pharmaceutical business enterprise anticipates launching the remedy inside the United States in April.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Bleeding Disorders Treatment Market size was valued at USD 14.29 Billion in 2022 and is poised to grow from USD 15.48 Billion in 2023 to USD 29.29 Billion by 2031, at a CAGR of 8.3% during the forecast period (2024-2031). 

The aggressive surroundings of the Bleeding Disorders Treatment marketplace is dynamic and is characterized via the presence of major pharmaceutical companies and biotechnology corporations striving to establish a sturdy marketplace foothold. Established gamers including Novo Nordisk, Shire (now part of Takeda), and Bayer dominate the marketplace with considerable portfolios of clotting issue merchandise and advancements in remedy alternatives. These enterprise leaders continually spend money on studies and improvement to introduce novel treatment plans, ensuring a aggressive aspect. 'Takeda Pharmaceutical Company Limited ', 'Bayer AG ', 'Biogen Inc. ', 'CSL Behring (CSL Limited) ', 'Novo Nordisk A/S ', 'Pfizer Inc. ', 'Grifols SA ', 'Sanofi S.A. ', 'Johnson & Johnson ', 'Octapharma AG '

Rising Focus On Personalized Medicine: The growing cognizance on personalised medicine, tailoring remedies to man or woman affected person profiles to optimize efficacy and decrease damaging results. Advances in gene remedy are rising as a transformative trend, with ongoing research and scientific trials showcasing the ability for a curative method to positive bleeding issues. Additionally, prophylactic treatments are gaining prominence, emphasizing the preventive management of bleeding episodes in preference to reactive interventions.

North America, especially the USA, is expected to dominate the bleeding disorders treatment market. The place has a properly-established healthcare infrastructure, higher incidence of bleeding issues, and vast cognizance approximately superior treatment options. Access to novel treatment plans and a excessive stage of studies and development activities make contributions to North America's dominance. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Bleeding Disorders Treatment Market

Report ID: SQMIG35J2106

$5,300
BUY NOW GET FREE SAMPLE